搜索临床试验以:A2:SHR-A1811 与 Camrelizumab
总计247个结果
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.尚未招聘
-
Jiangsu HengRui Medicine Co., Ltd.尚未招聘
-
Jiangsu HengRui Medicine Co., Ltd.Atridia Pty Ltd.招聘中
-
Cancer Institute and Hospital, Chinese Academy...招聘中
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.招聘中
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.招聘中
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.招聘中
-
Jiangsu HengRui Medicine Co., Ltd.招聘中先前接受过曲妥珠单抗和紫杉烷治疗的 HER2 阳性、不可切除和/或转移性乳腺癌受试者中国
-
Jiangsu HengRui Medicine Co., Ltd.尚未招聘HER2 阳性复发性或转移性乳腺癌
-
Zhejiang Cancer Hospital尚未招聘胃癌、HIPEC、抗 PD-1 抗体 Camrelizumab (SHR-1210)、化疗和手术中国
-
Shanghai Ninth People's Hospital Affiliated to...招聘中
-
Hospital of Stomatology, Wuhan UniversityJiangsu HengRui Medicine Co., Ltd.招聘中
-
Hospital of Stomatology, Wuhan UniversityJiangsu HengRui Medicine Co., Ltd.主动,不招人
-
Tianjin Medical University Cancer Institute and...尚未招聘
-
Fudan University招聘中乳腺癌 | 乳腺肿瘤 | 乳腺肿瘤 | HER2阳性乳腺癌 | 局部晚期乳腺癌 | HER2 阴性乳腺癌 | 激素受体阳性肿瘤 | 激素受体阴性肿瘤 | 早期乳腺癌 | 三阴性乳腺癌 (TNBC)中国
-
Jiangsu HengRui Medicine Co., Ltd.招聘中
-
Cancer Institute and Hospital, Chinese Academy...招聘中
-
Peking Union Medical College Hospital招聘中
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.邀请报名
-
Shanghai Chest Hospital尚未招聘